Company Overview and News

9
The No.1 Story In Cannabis Markets Today

2018-10-02 oilprice - 4
Your license and viewing of our content is subject to the disclosures contained after this article.
TBQBF THCBF NTEC CGC DALR THC DRLDF TLFTD EMH DNA.WT.A APH EMHTF DRRLF WEED CNTTF APHQF DGE DGE OGRMF DEO OGI DNA

9
Why Is Apple Giving This Tiny Stock A $900 Million Opportunity?

2018-09-16 oilprice - 6
Your license and viewing of our content is subject to the disclosures contained after this article.
SHOP AWSM DSGX DALR BBRY DRLDF DNA.WT.A APH DRRLF CLS APHQF BB DNA

1
Why Is Apple Giving This Tiny Stock A $900 Million Opportunity?

2018-09-13 oilprice - 1
Your license and viewing of our content is subject to the disclosures contained after this article.
DRLDF DNA.WT.A AWSM APH DRRLF APHQF DALR DNA

 
Orion completes acquisition of Dalradian

2018-09-07 globenewswire
TORONTO, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) and Orion Mine Finance (“Orion”) are pleased to announce the completion of the previously announced plan of arrangement (the “Transaction”) and that all required approvals have been obtained and all required conditions satisfied.
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian receives final court order approving arrangement

2018-09-04 globenewswire
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that it has received a final order from the Ontario Superior Court of Justice (Commercial List) approving the previously announced plan of arrangement (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Scythian Biosciences Corp. Announces Andy DeFrancesco as a New Director

2018-09-04 globenewswire
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) announced today that it has appointed Andrew DeFrancesco to the Board of Directors effective September 4, 2018.
PXT PARXF AWSM DALR EPS EPSEF DRLDF DNA.WT.A APH DRRLF LHSIF APPCQ APHQF DNA

 
Dalradian shareholders overwhelmingly approve arrangement

2018-08-31 globenewswire
TORONTO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that at a special meeting of its shareholders held today, its shareholders overwhelmingly approved the previously announced plan of arrangement (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian shareholders overwhelmingly approve arrangement

2018-08-31 globenewswire
TORONTO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that at a special meeting of its shareholders held today, its shareholders overwhelmingly approved the previously announced plan of arrangement (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Further to shareholder meeting

2018-08-22 globenewswire
TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading independent proxy advisory firms, have both recommended that Dalradian shareholders vote FOR the previously announced transaction (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
ISS and Glass Lewis recommend Dalradian shareholders vote FOR the arrangement

2018-08-22 globenewswire
TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading independent proxy advisory firms, have both recommended that Dalradian shareholders vote FOR the previously announced transaction (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian Announces Shareholding

2018-08-17 globenewswire
TORONTO, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA; AIM:DALR) (“Dalradian” or the “Company”) was given notice on 16 August 2018 of a shareholding by LMR Partners LLP (“LMR Partners”). According to the notice, LMR Partners has purchased 11,907,200 common shares and as of 16 August 2018, LMR Partners beneficially held 26,900,000 common shares representing 7.57% of the issued share capital of the Company based on Dalradian’s outstanding shares of 355,493,448.
DRLDF DNA.WT.A DRRLF DALR DNA

 
Notice of GM

2018-08-10 globenewswire
TORONTO, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that it has mailed its management information circular, related voting materials and letter of transmittal (collectively, the “Meeting Materials”) to its shareholders in connection with the special meeting (the “Meeting”) of Dalradian’s shareholders to consider the previously announced transaction with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian mails shareholder materials for August 31 meeting

2018-08-10 globenewswire
TORONTO, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that it has mailed its management information circular, related voting materials and letter of transmittal (collectively, the “Meeting Materials”) to its shareholders in connection with the special meeting (the “Meeting”) of Dalradian’s shareholders to consider the previously announced transaction with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian reports Q2 2018 results with cash of $120 million at June 30, 2018

2018-08-09 globenewswire
TORONTO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA; AIM:DALR) (“Dalradian” or the “Company”) announces results for the three and six months ended June 30, 2018, including closing cash and cash equivalents of $120 million (all amounts are quoted in Canadian dollars).
DRLDF DNA.WT.A OKSWF DRRLF OR LNSTY OSKGF DALR DNA

 
Dalradian receives interim order setting shareholder meeting for August 31

2018-08-03 globenewswire
TORONTO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA)(AIM:DALR) (“Dalradian” or the “Company”) is pleased to announce that Dalradian has been granted an interim order (the “Interim Order”) authorizing various matters including the holding of a special meeting (the “Meeting”) of Dalradian’s shareholders to consider the previously announced transaction with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:DNA / Dalradian Resources Inc. on message board site Silicon Investor.

MDNA (MC C$36 M) Cash (C$20 M) Approval on P2 Data MDNA (MC C$36 M) Cash (C$20 M) Approval on P2 Data MDNA (MC C$36 M) Cash (C$20 M) Approval on P2 Data DNAG - DNAPrint Genomics DNAG - DNAPrint Genomics DNAG - DNAPrint Genomics
Complete Genomics GNOM DNA analysis for human genome Complete Genomics GNOM DNA analysis for human genome Complete Genomics GNOM DNA analysis for human genome Genentech (NYSE:DNA) formerly known as (NYSE:GNE) Genentech (NYSE:DNA) formerly known as (NYSE:GNE) Genentech (NYSE:DNA) formerly known as (NYSE:GNE)
Commonwealth Biotechnologies CBTE - Genomics/DNA Seq Commonwealth Biotechnologies CBTE - Genomics/DNA Seq Commonwealth Biotechnologies CBTE - Genomics/DNA Seq MTDX - Motion DNA Corporation MTDX - Motion DNA Corporation MTDX - Motion DNA Corporation
LDNA-LARK TECHNOLOGIES LDNA-LARK TECHNOLOGIES LDNA-LARK TECHNOLOGIES DNAP unlocking DNA coding DNAP unlocking DNA coding DNAP unlocking DNA coding
LDNA: Lark Technologies, Inc. LDNA: Lark Technologies, Inc. LDNA: Lark Technologies, Inc. SEDONA Corporation (SDNA) SEDONA Corporation (SDNA) SEDONA Corporation (SDNA)